* subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent; * sars-cov-2 infection by pcr ≥ 96h; * platelet (plt) \< 50×10\^9/l, or hemoglobin (hgb) \< 60g/l; * total bilirubin (tbil) \> 2×uln (upper limit of normal value), or alanine transferase (alt), aspartate transferase (ast), alkaline phosphatase (alp) \> 5×uln; * glomerular filtration rate (gfr) \< 30ml/min·1.73m\^2, or serum creatinine increased by 0.5mg/ dl within 7 days, or oliguria (\<400ml/24hr), or anuria (\<100ml/24hr); * pregnant or breast feeding; * persons who have family planning or do not agree to use effective non-drug contraceptive measures within 6 months after signing the icf; * subjects participating in another clinical study. there will be a need for washout with 5 half lives depending on the study treatment or 30 days since any previous study, whichever is longer; * he inestigators concluded that the patients had other reasons for not being eligible for the study.

* subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent; * sars-cov-2 infection by pcr ≥ 96h; * platelet (plt) \< 50×10\^9/l, or hemoglobin (hgb) \< 60g/l; * total bilirubin (tbil) \> 2×uln (upper limit of normal value), or alanine transferase (alt), aspartate transferase (ast), alkaline phosphatase (alp) \> 5×uln; * glomerular filtration rate (gfr) \< 30ml/min·1.73m\^2, or serum creatinine increased by 0.5mg/ dl within 7 days, or oliguria (\<400ml/24hr), or anuria (\<100ml/24hr); * pregnant or breast feeding; * persons who have family planning or do not agree to use effective non-drug contraceptive measures within 6 months after signing the icf; * subjects participating in another clinical study. there will be a need for washout with 5 half lives depending on the study treatment or 30 days since any previous study, whichever is longer; * he inestigators concluded that the patients had other reasons for not being eligible for the study.

- subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent; - sars-cov-2 infection by pcr ≥ 96h; - platelet (plt) < 50×10^9/l, or hemoglobin (hgb) < 60g/l; - total bilirubin (tbil) > 2×uln (upper limit of normal value), or alanine transferase (alt), aspartate transferase (ast), alkaline phosphatase (alp) > 5×uln; - glomerular filtration rate (gfr) < 30ml/min·1.73m^2, or serum creatinine increased by 0.5mg/ dl within 7 days, or oliguria (<400ml/24hr), or anuria (<100ml/24hr); - pregnant or breast feeding; - persons who have family planning or do not agree to use effective non-drug contraceptive measures within 6 months after signing the icf; - subjects participating in another clinical study. there will be a need for washout with 5 half lives depending on the study treatment or 30 days since any previous study, whichever is longer; - he inestigators concluded that the patients had other reasons for not being eligible for the study.

- subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent; - sars-cov-2 infection by pcr ≥ 96h; - platelet (plt) < 50×10^9/l, or hemoglobin (hgb) < 60g/l; - total bilirubin (tbil) > 2×uln (upper limit of normal value), or alanine transferase (alt), aspartate transferase (ast), alkaline phosphatase (alp) > 5×uln; - glomerular filtration rate (gfr) < 30ml/min·1.73m^2, or serum creatinine increased by 0.5mg/ dl within 7 days, or oliguria (<400ml/24hr), or anuria (<100ml/24hr); - pregnant or breast feeding; - persons who have family planning or do not agree to use effective non-drug contraceptive measures within 6 months after signing the icf; - subjects participating in another clinical study. there will be a need for washout with 5 half lives depending on the study treatment or 30 days since any previous study, whichever is longer; - he inestigators concluded that the patients had other reasons for not being eligible for the study.